# Capecitabine

## Calveda 500mg

| TAH Drug Code      | [OCAP5](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OCAP5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Breast cancer， colon cancer or colorectal cancer (colon-rectal cancer)， stomach cancer.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Dosing             | Adjuvant treatment is recommended for a total of 6 months (8 cycles) [Metastatic Colorectal Cancer， Adjuvant Colorectal Cancer， Dukes’ C colon cancer (adjuvant treatment)] 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest period given as 3-week cycles for a total of 8 cycles (24 weeks) [Metastatic Breast Cancer] Monotherapy: 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest period given as 3-week cycles; Combination: 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest period， combined with docetaxel at 75 mg/m2 as a 1-hour intravenous infusion every 3 weeks. |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Contraindications  | Known hypersensitivity to capecitabine， fluorouracil， or any component of the formulation; severe renal impairment (CrCl <30 mL/minute). Canadian labeling: Additional contraindications (not in the US labeling): Known complete absence of dihydropyrimidine dehydrogenase (DPD) activity; concomitant administration with sorivudine or chemically related analogues (eg， brivudine).                                                                                                                                                                                                                            |
| Adverse Effects    | GI disturbances; hand-foot syndrome， alopecia， pruritus， rash; fatigue， pyrexia， lethargy， asthenia; dizziness， taste disturbance; anorexia; conjunctivitis; neutropenia. Dermatologic: Dermatitis (27% to 37% ) Gastrointestinal: Abdominal pain， Constipation， Loss of appetite， Nausea， Stomatitis， Vomiting Other: Fatigue                                                                                                                                                                                                                                                                             |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| More Info          | [UpToDate](https://www.uptodate.com/contents/capecitabine-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

